Medicure Inc. said it was holding off on the launch of a heart treatment called Prexxartan due to a dispute.

Medicure acquired the rights to sell the drug in the U.S. and its territories in October 2017 from Carmel Biosciences Inc., which originally developed the treatment for hypertension and heart failure, as well as for the reduction of heart-related deaths.

However, Carmel is now in a dispute with the third-party manufacturer of the product, prompting Medicure to hold off on the launch.

The Canadian pharmaceutical company intended to launch Prexxartan in the first half of 2018. The company also said it has so far made an up-front payment of $100,000 to Carmel for Prexxartan.